Trial Profile
A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms TBCRC 006
- 25 Oct 2019 Results assessing predictive role of Tumor infiltrating lymphocytes were published in the Clinical Cancer Research
- 23 Mar 2019 Results of an exploratory analysis of HER2 gene amplification, ER status and other markers along the HER2/ER signaling axis, published in the Annals of Oncology
- 05 Jun 2018 Results evaluating the value of the HER2-E subtype and ERBB2 mRNA expression alone to predict pathological complete response (pCR) in tumor samples from PAMELA and TBCRC 006/023 trials presented at the 54th Annual Meeting of the American Society of Clinical Oncology